Probiotic drug interactions in ulcerative colitis: a microbiota and metabolite perspective
Jana Štofilová, Veronika Benetinová, Izabela Bertková, Zuzana Hanzelová, Anna Kamlárová, Monika Kvaková · 2026
Read Probiotic drug interactions in ulcerative colitis: a microbiota and metabolite perspective by Jana Štofilová, Veronika Benetinová, Izabela Bertková, Zuzana Hanzelová, Anna Kamlárová, Monika Kvaková (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13625272.txt.
Description
Ulcerative colitis treatment increasingly involves live bacteria, and Jana Štofilová and co-authors review the two-way street between probiotics and the drugs they accompany, in a 2026 article. The young science behind this studies how gut microbes chemically rework drugs, tune the body's drug-handling machinery, and change how medicines act.
Selected probiotic formulas genuinely help induce and hold remission in colitis, the review grants. But a probiotic is not a neutral bystander: it can transform a drug, compete with it, or amplify its effects, for better or worse. The authors survey this interaction landscape through the lens of microbes and their metabolites, the small molecules that carry many of the effects. Their aim is practical: help clinicians pair probiotics with standard therapy on purpose, with doses and strains chosen for the drug regimen, not added on hope.
Catalog record
| CREATOR | Jana Štofilová, Veronika Benetinová, Izabela Bertková, Zuzana Hanzelová, Anna Kamlárová, Monika Kvaková |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 103 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |